Solid Biosciences is advancing two gene therapy programs—one for Duchenne muscular dystrophy and another for Friedreich’s ataxia—with regulatory tests looming as the company prepares for critical FDA meetings in late 2026 and early 2027. The biotech, led by President and CEO Bo Cumbo, highlighted progress in its Phase III confirmatory trial for Duchenne (IMPACT DUCHENNE) and early-stage work on SGT-601 for Friedreich’s ataxia, while also expanding its AAV capsid platform to support up to 100–200 programs over the next three to five years.
For Duchenne, Solid Biosciences has dosed a 53-patient cohort in the INSPIRE trial, with 12 patients now having at least one year of follow-up. The company expects to present preliminary data from this cohort at a Q4 2026 FDA meeting, where it will present a mix of biomarker and functional endpoints, including measures of muscle integrity and mobility. The FDA has acknowledged the program’s high unmet need and its novelty, reinforcing Solid’s position as a non-me-too therapy. The company is also preparing for an accelerated approval discussion, with a potential Biologics License Application (BLA) filing targeted for late 2027 if the FDA deems the data sufficient and manufacturing compliance (CMC) work is complete.
Meanwhile, Solid’s Friedreich’s ataxia program, SGT-601, has dosed three patients, with plans to reach seven by year-end 2026. The dual-mode administration involves stereotactic intracerebral delivery targeting the dentate nucleus, with a procedure duration of about four hours. The company has faced delays due to three consecutive screening failures tied to cardiac issues between March and August 2026. The Phase III trial, expected to enroll no more than 50 patients, will be double-blind and placebo-controlled, with a sham procedure consisting of a minor scalp nick and intravenous placebo. The first data from the initial two or three patients are anticipated in Q1 2027.
Solid’s AAV capsid platform, which includes 50 active licensing agreements, is advancing four to five additional capsids through non-human primate studies by year-end 2026. The company aims to reduce costs associated with traditional capsids, which can exceed $10 million, by leveraging its proprietary approach. Cumbo emphasized the platform’s potential to democratize gene therapy development, attracting smaller biotech firms that lack the resources for high-cost capsids.
Manufacturing progress is on track, with the third and final pre-clinical production campaign (PPQ3) underway. Solid is also building an internal artificial intelligence platform to analyze preclinical, CMC, and clinical data, draft regulatory documents, and compare patient outcomes with natural history controls. The company’s international sites for the Duchenne trial are expected to open by late 2026 to early 2027, expanding enrollment beyond Australia and Canada.
The timing of these milestones underscores Solid’s aggressive push toward regulatory approval, with the FDA meeting for Friedreich’s ataxia planned for the first half of 2027. If successful, the company could accelerate its platform’s commercialization, positioning itself as a leader in rare disease gene therapy.
